Dose-Dense Therapy in Aggressive Lymphoma
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma|
Drug: CEOP/IMVP-Dexa chemotherapy
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.